

## Supporting Information

### **Polymer-Lipid Hybrid Nanoparticles as Potential Lipophilic Anticancer Drug Carriers**

*Sedef Salel<sup>1</sup>, Banu Iyisan<sup>1,2\*</sup>*

<sup>1</sup>Biofunctional Nanomaterials Design (BiND) Laboratory, Institute of Biomedical Engineering, Bogazici University, 34684, Istanbul, Turkey

<sup>2</sup>Partner Group of Max Planck Institute for Polymer Research Mainz (Germany) at Bogazici University, 34684, Istanbul, Turkey

\*Corresponding author E-mail: [banu.iyisan@boun.edu.tr](mailto:banu.iyisan@boun.edu.tr)

## **Table of Contents for Supporting Information:**

### **1. Supporting Figures**

**Figure S1.** Scheme of Maillard Reaction between bovine serum albumin (BSA) and dextran.

**Figure S2.** FT-IR spectrum of (a) BSA, Dextran (molecular weight: 10 kDa), BSA-Dex10.2 and (b) BSA, Dextran (molecular weight: 70 kDa), BSA-Dex70.2.

**Figure S3.** Calibration Curve of BSA determined from absorbance values at  $\lambda = 655$  nm to calculate protein concentrations of each Maillard complex.

**Figure S4.** Calibration Curve of Paclitaxel determined from absorbance values at  $\lambda = 260$  nm at (a) pH 6.5, (b) pH 7.4.


**Figure S5.** Size Distribution Histogram of the Nanoparticles obtained from Scanning Transmission Electron Microscopy Images

**Figure S6.** (a) Size, Polydispersity index (PDI), and zeta potential values of SLPN\_TW20 (control nanoparticles synthesized using %1 v/v Tween 20). (b) Scanning Transmission Electron Microscopy (STEM) images of SLPN\_TW20 show the spherical morphology.



**Figure S7.** FT-IR spectrum of nanoparticles: SLPN10.1

**Table S1.** Zeta potential values of SLPN10.1 and SLPN\_TW20 (control nanoparticles) over the storage time of four months. Formulation ingredients of SLPN10.1 is in Table 1.


### **2. Statistical Analysis**




**Figure S1.** Scheme of Maillard Reaction between bovine serum albumin (BSA) and dextran Adapted from <sup>[1]</sup>.




**Figure S2.** FT-IR spectrum of (a) BSA (blue), Dextran (molecular weight: 10 kDa) (black), BSA-Dex10.2 (red) and (b) BSA (blue), Dextran (molecular weight: 70 kDa) (black), BSA-Dex70.2 (red).



**Figure S3.** Calibration Curve of BSA determined from absorbance values at  $\lambda = 655$  nm to calculate protein concentrations of each Maillard complex.




**Figure S4.** Calibration Curve of Paclitaxel determined from absorbance values at  $\lambda = 260 \text{ nm}$  at (a) pH 6.5, (b) pH 7.4.



**Figure S5.** Size Distribution Histogram of the Nanoparticles obtained from Scanning Transmission Electron Microscopy Images


	Average Size (nm)	Polydispersity Index	Zeta Potential (mV)
(a)	$143.2 \pm 0.8$	$0.25 \pm 0.03$	$-29.9 \pm 2.1$



**Figure S6.** (a) Size, Polydispersity index (PDI), and zeta potential values of SLPN\_TW20 (control nanoparticles synthesized using %1 v/v Tween 20). (b) Scanning Transmission Electron Microscopy (STEM) images of SLPN\_TW20 show the spherical morphology

**Table S1.** Zeta potential values of SLPN10.1 and SLPN\_TW20 (control nanoparticles) over the storage time of four months. Formulation ingredients of SLNP10.1 is in Table 1.

Stability Check	SLPN10.1		SLPN_TW20	
	t = 0	t = 4 months	t = 0	t = 4 months
Zeta Potential (mV)	-40.7 ± 0.1	-42.2 ± 0.4	-29.9 ± 2.1	-27.9 ± 0.5



**Figure S7.** FT-IR spectrum of nanoparticles: SLPN10.1.

### Statistical Analysis

The drug release experiments were conducted in triplicate, and the cumulative release (%) data are reported as the mean ± standard deviation (SD) of the three independent measurements. Statistical analysis were performed using two-way ANOVA through Matlab “anova2” function. Results were considered significant at 95% confidence interval ( $p < 0.05$ ). We have conducted analysis for drug release results both at pH 7.4 and at pH 6.5. Both enzyme ( $p=0.0001$  at pH 7.4,  $p=0.0001$  at pH 6.5) and time ( $p=0.0005$  at pH 7.4,  $p<0.0001$  at pH 6.5) have a statistically significant effect on drug release since  $p<0.05$ .

### References

[1] T. Wang, J. Xue, Q. Hu, M. Zhou, C. Chang, Y. Luo, *Sci. Rep.* **2017**, 7.